Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11738566rdf:typepubmed:Citationlld:pubmed
pubmed-article:11738566lifeskim:mentionsumls-concept:C0330390lld:lifeskim
pubmed-article:11738566lifeskim:mentionsumls-concept:C0002482lld:lifeskim
pubmed-article:11738566lifeskim:mentionsumls-concept:C0052350lld:lifeskim
pubmed-article:11738566lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:11738566lifeskim:mentionsumls-concept:C1441547lld:lifeskim
pubmed-article:11738566lifeskim:mentionsumls-concept:C0243076lld:lifeskim
pubmed-article:11738566lifeskim:mentionsumls-concept:C1707494lld:lifeskim
pubmed-article:11738566pubmed:issue1lld:pubmed
pubmed-article:11738566pubmed:dateCreated2001-12-12lld:pubmed
pubmed-article:11738566pubmed:abstractTextMimetics of the RGD tripeptide are described that are potent, selective antagonists of the integrin receptor, alpha(v)beta(3). The use of the 5,6,7,8-tetrahydro[1,8]naphthyridine group as a potency-enhancing N-terminus is demonstrated. Two 3-substituted-3-amino-propionic acids previously contained in alpha(IIb)beta(3) antagonists were utilized to enhance binding affinity and functional activity for the targeted receptor. Further affinity increases were then achieved through the use of cyclic glycyl amide bond constraints.lld:pubmed
pubmed-article:11738566pubmed:languageenglld:pubmed
pubmed-article:11738566pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11738566pubmed:citationSubsetIMlld:pubmed
pubmed-article:11738566pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11738566pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11738566pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11738566pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11738566pubmed:statusMEDLINElld:pubmed
pubmed-article:11738566pubmed:monthJanlld:pubmed
pubmed-article:11738566pubmed:issn0960-894Xlld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:MeissnerRober...lld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:PerkinsJames...lld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:DuongLe Tle Tlld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:HartmanGeorge...lld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:HoffmanWillia...lld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:HuffJoel RJRlld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:IhleNathan...lld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:LeuChih TaiCTlld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:NagyRose MRMlld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:Naylor-OlsenA...lld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:RodanGideon...lld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:RodanSevgi...lld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:WhitmanDavid...lld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:WesolowskiGre...lld:pubmed
pubmed-article:11738566pubmed:authorpubmed-author:DugganMark...lld:pubmed
pubmed-article:11738566pubmed:issnTypePrintlld:pubmed
pubmed-article:11738566pubmed:day7lld:pubmed
pubmed-article:11738566pubmed:volume12lld:pubmed
pubmed-article:11738566pubmed:ownerNLMlld:pubmed
pubmed-article:11738566pubmed:authorsCompleteYlld:pubmed
pubmed-article:11738566pubmed:pagination25-9lld:pubmed
pubmed-article:11738566pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:11738566pubmed:meshHeadingpubmed-meshheading:11738566...lld:pubmed
pubmed-article:11738566pubmed:meshHeadingpubmed-meshheading:11738566...lld:pubmed
pubmed-article:11738566pubmed:meshHeadingpubmed-meshheading:11738566...lld:pubmed
pubmed-article:11738566pubmed:meshHeadingpubmed-meshheading:11738566...lld:pubmed
pubmed-article:11738566pubmed:meshHeadingpubmed-meshheading:11738566...lld:pubmed
pubmed-article:11738566pubmed:meshHeadingpubmed-meshheading:11738566...lld:pubmed
pubmed-article:11738566pubmed:meshHeadingpubmed-meshheading:11738566...lld:pubmed
pubmed-article:11738566pubmed:meshHeadingpubmed-meshheading:11738566...lld:pubmed
pubmed-article:11738566pubmed:meshHeadingpubmed-meshheading:11738566...lld:pubmed
pubmed-article:11738566pubmed:meshHeadingpubmed-meshheading:11738566...lld:pubmed
pubmed-article:11738566pubmed:meshHeadingpubmed-meshheading:11738566...lld:pubmed
pubmed-article:11738566pubmed:meshHeadingpubmed-meshheading:11738566...lld:pubmed
pubmed-article:11738566pubmed:meshHeadingpubmed-meshheading:11738566...lld:pubmed
pubmed-article:11738566pubmed:year2002lld:pubmed
pubmed-article:11738566pubmed:articleTitleNonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide.lld:pubmed
pubmed-article:11738566pubmed:affiliationDepartment of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. robert_meissner@merck.comlld:pubmed
pubmed-article:11738566pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:11738566lld:chembl